Trial · NCT04564898

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

NCT04564898, Phase 1, Phase 2, Active not recruiting, Gruppo Oncologico del Nord-Ovest

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. Trials, record NCT04564898. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04564898

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT number: NCT04564898
Status: Active not recruiting
Phases: Phase 1, Phase 2
Enrollment: 48 participants, estimated
Lead sponsor: Gruppo Oncologico del Nord-Ovest
Conditions: Colorectal Cancer Metastatic
Interventions: Capecitabine, Bevacizumab, Trifluridine/Tipiracil
First posted: 2020-09-25
Last updated: 2026-05-20

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	recommended dose	2 years	recommended dose of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab
Primary	activity	3 years	activity of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of overaal response rate per RECIST v1.1.
Secondary	quality of life for cancer patients	3 years	quality of life as measured by EORTC QLQ-C30 questionnaire.
Secondary	quality of life for colorectal cancer patients	3 years	quality of life as measured by EORTC QLQ-CR29 questionnaire.
Secondary	quality of life for dimensions health	3 years	quality of life as measured by EuroQol EQ-5D questionnaire.
Secondary	survival	3 years	efficacy of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of progression-free survival and overall survival
Other	bioavailability	2 years	Absolute and relative bioavailability of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Steady state concentration	2 years	Steady state concentration of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Therapeutic index	2 years	Therapeutic index of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Volume of distribution	2 years	Volume of distribution of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04564898

GET https://conductscience.org/api/trials/v1/NCT04564898/registered

API reference For AI assistants